CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Class A Common Stock	Common Stock Class A Common Stock	Common Stock Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2016			52,587	15,347
Beginning balance at Dec. 31, 2016	$ 912,114		$ 506	$ 153	$ 555,250	$ 0	$ 146,617	$ 209,588
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	20,437				20,437
Exercise of stock options (in shares)			788
Exercise of stock options	4,082		$ 28		4,054
Restricted stock units vested, net of shares withheld for taxes (in shares)			149
Restricted stock units vested, net of shares withheld for taxes	(1,272)		$ 2		(1,274)
Shares released from Valence Health escrow (in shares)			(310)
Shares released from Valence Health escrow	908		$ (3)		911
Exchange of Class B common stock (in shares)			12,693	(12,693)
Exchange of Class B common stock	0		$ 126	$ (126)	168,883			(168,883)
Tax impact of 2017 Securities Offerings	12,857				12,857
Issuance of common stock (in shares)		20,100	8,816
Issuance of common stock	166,947		$ 88		166,859
Foreign currency translation adjustment	0
Net loss	(69,767)						(60,665)	(9,102)
Reclassification of non-controlling interests	0				(3,824)			3,824
Ending balance (in shares) at Dec. 31, 2017			74,723	2,654
Ending balance at Dec. 31, 2017	1,046,306		$ 747	$ 27	924,153	0	85,952	35,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	17,221				17,221
Exercise of stock options (in shares)			1,720
Exercise of stock options	11,929		$ 16		11,913
Restricted stock units vested, net of shares withheld for taxes (in shares)			212
Restricted stock units vested, net of shares withheld for taxes	(1,236)		$ 2		(1,238)
Shares released from Valence Health escrow (in shares)			(67)
Shares released from Valence Health escrow	(1,003)		$ 0		(1,003)
Exchange of Class B common stock (in shares)			2,584	(2,584)
Exchange of Class B common stock	0		$ 27	$ (27)	34,682			(34,682)
Tax impact of 2017 Securities Offerings	652				652
Issuance of common stock (in shares)				3,120
Issuance of common stock	83,173			$ 31	40,355			42,787
Equity component of 2025 Notes, net of issuance costs	69,378				69,378
Foreign currency translation adjustment	(182)					(182)
Net loss	(54,191)						(52,658)	(1,533)
Reclassification of non-controlling interests	0				(2,939)			2,939
Ending balance (in shares) at Dec. 31, 2018			79,172	3,190
Ending balance at Dec. 31, 2018	1,189,356		$ 792	$ 31	1,093,174	(182)	50,009	45,532
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 16,006				16,006
Exercise of stock options (in shares)	138		138
Exercise of stock options	$ 1,092		$ 1		1,091
Restricted stock units vested, net of shares withheld for taxes (in shares)			363
Restricted stock units vested, net of shares withheld for taxes	(2,609)		$ 4		(2,613)
Exchange of Class B common stock (in shares)			3,146	(3,146)
Exchange of Class B common stock	0		$ 31	$ (31)	42,377			(42,377)
Tax impact of 2017 Securities Offerings	(22)				(22)
Issuance of common stock (in shares)			3,100
Share retirement (in shares)			(5)	(44)
Class A common stock issued for Passport earn-out (in shares)			43
Class A common stock issued for Passport earn-out	800				800
Amount attributable to NCI from business combination	6,500							6,500
Shares issued for equity-method investments and asset acquisitions (in shares)			1,732
Shares issued for equity-method investments and asset acquisitions	23,556		$ 18		23,538
Foreign currency translation adjustment	(52)					(52)
Net loss	(305,580)						(301,971)	(3,609)
Reclassification of non-controlling interests	0				(643)			643
Ending balance (in shares) at Dec. 31, 2019			84,589	0
Ending balance at Dec. 31, 2019	$ 929,047		$ 846	$ 0	$ 1,173,708	$ (234)	$ (251,962)	$ 6,689